30-Jan-2025 5:09 AM CST - Yahoo Finance Here's Why You Should Add PODD Stock to Your Portfolio Now Focus on Market Expansion and Operational Excellence: Insulet is expanding its global presence in a targeted and strategic manner. The company is now shifting from Omnipod GO to Omnipod 5 as its primary offering for people with type 2 diabetes on basal-only insulin. Omnipod 5 is driving strong customer adoption from all market segments.
27-Jan-2025 7:43 AM CST - Barchart Earnings Preview: What to Expect From Insulet's Report Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Valued at a market cap of $19.7 billion, the company's Omnipod Insulin Management System is equipped with a self-adhesive,
10-Jan-2025 5:00 AM CST - Business Wire Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available
8-Jan-2025 5:35 PM CST - Business Insider Insulet price target raised to $315 from $305 at Bernstein Bernstein raised the firm's price target on Insulet (PODD) to $315 from $305 and keeps an Outperform rating on the shares as part of a broader
3-Jan-2025 4:14 AM CST - Business Insider Insulet price target raised to $324 from $264 at TD Cowen TD Cowen raised the firm's price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will
2-Jan-2025 10:16 PM CST - Business Insider TD Cowen Reaffirms Their Buy Rating on Insulet (PODD) In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Insulet (PODD - Research Report), with a price target of
30-Dec-2024 6:15 AM CST - Business Insider Insulet price target raised to $300 from $270 at BTIG BTIG raised the firm's price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note
30-Jan-2025 5:09 AM CST - Yahoo Finance Here's Why You Should Add PODD Stock to Your Portfolio Now Focus on Market Expansion and Operational Excellence: Insulet is expanding its global presence in a targeted and strategic manner. The company is now shifting from Omnipod GO to Omnipod 5 as its primary offering for people with type 2 diabetes on basal-only insulin. Omnipod 5 is driving strong customer adoption from all market segments.
27-Jan-2025 7:43 AM CST - Barchart Earnings Preview: What to Expect From Insulet's Report Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Valued at a market cap of $19.7 billion, the company's Omnipod Insulin Management System is equipped with a self-adhesive,
10-Jan-2025 5:00 AM CST - Business Wire Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available
8-Jan-2025 5:35 PM CST - Business Insider Insulet price target raised to $315 from $305 at Bernstein Bernstein raised the firm's price target on Insulet (PODD) to $315 from $305 and keeps an Outperform rating on the shares as part of a broader
3-Jan-2025 4:14 AM CST - Business Insider Insulet price target raised to $324 from $264 at TD Cowen TD Cowen raised the firm's price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will
2-Jan-2025 10:16 PM CST - Business Insider TD Cowen Reaffirms Their Buy Rating on Insulet (PODD) In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Insulet (PODD - Research Report), with a price target of
30-Dec-2024 6:15 AM CST - Business Insider Insulet price target raised to $300 from $270 at BTIG BTIG raised the firm's price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note